Review Reports
- Preanka Mudaly,
- Max Lee and
- Craig Thompson *
- et al.
Reviewer 1: Martha Pedraza-Escalona Reviewer 2: Anonymous
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsThe current version of the review entitled Advances in the Development of a Universal Influenza Vaccinecomprehensively evaluates the advantages and limitations of various universal influenza vaccine (UIV) strategies targeting the hemagglutinin (HA) stalk, internal viral proteins, and whole-virus formulations. It also compares their immunogenicity, protective efficacy, manufacturing challenges, and economic considerations, including the potential of artificial intelligence to optimize antigen design for the induction of broad and durable immune responses. The review is well written. Only I have some comments:
-Please expand in the Introduction section the limitations and disadvantages associated with the seasonal influenza vaccines (SIVs)
-Please, include Figure 2 in the Introduction section to illustrate the structural components of the viral targets used for UIV developments and SIVs
-Please expand the Discussion section to explain the reasons why these vaccine candidates have or have not been received approval from regulatory agencies.
Author Response
Comment 1: Please expand in the Introduction section the limitations and disadvantages associated with the seasonal influenza vaccines (SIVs)
Response 1: We thank the reviewer for their comment and pointing this out. We agree with this comment. Therefore, we have expanded on the limitations of the seasonal vaccines. The revised material can be found on page 2, paragraph 4, lines 21-27.
“There are several further limitations of current SIVs. Widespread reliance on egg-based vaccine production is a lengthy process and may introduce adaptive mutations that alter antigenicity and compromise vaccine performance [7,11]. Dependence on conventional egg-based manufacturing also limits production flexibility and rapid scalability in response to emerging influenza threats [7,11]. Additionally, SIV induced immunity is predominately strain-specific, providing limited cross-reactivity against antigenically distinct strains and little protection against emerging pandemic viruses [11,14].“
Comment 2: Please, include Figure 2 in the Introduction section to illustrate the structural components of the viral targets used for UIV developments and SIVs
Response 2: We thank the reviewer for their comment and pointing this out. We agree with this comment. Therefore, we have moved figure 2 to the introduction section. The material can be found on page 3.
Comment 3: Please expand the Discussion section to explain the reasons why these vaccine candidates have or have not been received approval from regulatory agencies.
Response 3: We thank the reviewer for their comment and pointing this out. We agree with this comment. Therefore, we have explained in the discussion section why candidates have not yet received regulatory approval as many of them have not yet progressed far enough for this. The revised material can be found on page 12, paragraph 5, lines 32-38.
“Despite encouraging preclinical findings and favourable early-phase clinical trials results, no UIV has yet received regulatory approval, this largely reflects the developmental stage of current candidates as most remain in phase 1 or 2 clinical evolution [48,65-90]. In addition, regulatory agencies require robust evidence of safety, durability and clinical efficacy across large, diverse populations, which has yet to be demonstrated. Much of this information relies on results from phase 3 clinical trials which are yet to be completed for UIV candidates [14,167,168].”
Reviewer 2 Report
Comments and Suggestions for AuthorsComments to the authors of Antibodies manuscript antibodies-4434376:
The authors of the manuscript "Advances in the Development of a Universal Influenza Vaccine" review the literature related to universal influenza vaccine development. The overall need for a universal influenza vaccine is clearly presented, and the feasibility is evident. In the review, the preclinical and clinical findings are presented and discussed, along with challenges related to long-term efficacy associated with immune imprinting and genetic plasticity of influenza viruses. These concerns bring into question whether a single vaccine formulation will be a solution to this problem. Below are some comments that I would like the authors to address as they revise this manuscript:
- The clinical trial progression timeline is useful and appreciated; the accompanying Table 1 helps as well. However, it might be possible to find a better way to present these so that they are in a single figure rather than a Figure/Table format. It just gets to be a bit difficult to navigate as a reader.
- The same can be said about Table 2 and Figure 2.
- In reading these universal vaccine approaches, one wonders about the proposed real-world delivery of these vaccines. Are these meant to replace the current vaccines or to complement them? Would these be given at the same time as current vaccines or at different times? One could envision that a universal influenza vaccine given once every 2-3 years could induce this broad immunity that complements annual vaccine-induced immunity. Thus, if there is a mismatch from the globular head-directed immunity that traditionally protects against influenza virus infection, our immune system already has an immune response prepared to eliminate the pathogen using the conserved antigens.
- Do the authors have a solution for the correlates of immunity problem? This has been discussed for years, but until reasonable solutions are identified and considered, we will not be able to address this concern
- The authors should discuss how well-received they think these infection-permissive vaccines will be by vaccine recipients.
- It seems that the immunological imprinting aspect could be overcome with a proper balance of seasonal vaccine and different universal vaccines. However, this would need to be tightly coordinated to enhance immunity appropriately in individual patients. This may be a theoretical possibility that may not be achievable in a real-world setting.
Author Response
Comments 1: The clinical trial progression timeline is useful and appreciated; the accompanying Table 1 helps as well. However, it might be possible to find a better way to present these so that they are in a single figure rather than a Figure/Table format. It just gets to be a bit difficult to navigate as a reader.
Response 1: We thank the reviewer for their comment and pointing this out. We agree with this comment. Therefore, we have combined the figure and the table so that the information is now condensed into one cohesive figure instead. The revised material can be found on page 4.
Comment 2: The same can be said about Table 2 and Figure 2.
Response 2: We thank the reviewer for their comment and pointing this out. We agree that the original placement of this figure alongside table 2 was not as coherent to navigate as it could be. Therefore, we have relocated figure 2 to the introduction section where it provides an overview and support of information as well as providing the reader with background information before reading table 2 (now table 1). The revised material can be found on page 3.
Comment 3: In reading these universal vaccine approaches, one wonders about the proposed real-world delivery of these vaccines. Are these meant to replace the current vaccines or to complement them? Would these be given at the same time as current vaccines or at different times? One could envision that a universal influenza vaccine given once every 2-3 years could induce this broad immunity that complements annual vaccine-induced immunity. Thus, if there is a mismatch from the globular head-directed immunity that traditionally protects against influenza virus infection, our immune system already has an immune response prepared to eliminate the pathogen using the conserved antigens.
Response 3: We thank the reviewer for their comment and pointing this out. We agree with this comment. Therefore, we have expanded the Discussion to include a new paragraph describing how the possible implementation of first-generation universal vaccines are likely to complement existing seasonal vaccines rather than serve as a full replacement. The revised material can be found in section ‘3.4 Manufacturing, Deployment and Economic Considerations’. The revised material can be found on page 12, paragraph 3, lines 12-22.
“Equally important is the consideration of how a UIV would be integrated into existing influenza immunisation programmes. Given that the majority of current candidates remain in early clinical development, it is unlikely that first-generation UIVs would immediately replace SIVs. Instead, they are more likely to complement existing vaccination strategies by establishing durable immunity against conserved viral antigens while annual SIVs continue to induce strain-specific neutralising antibodies against circulating strains [11,14]. This complementary approach, with periodic administration of UIVs alongside annual SIVs, could establish a baseline level of broad heterosubtypic immunity while maintaining protection against antigenic drift and reducing the impact of seasonal vaccine mismatch, although an optimal implementation strategy remains to be determined [14,31,50]. “
Comment 4: Do the authors have a solution for the correlates of immunity problem? This has been discussed for years, but until reasonable solutions are identified and considered, we will not be able to address this concern.
Response 4: We thank the reviewer for their comment and pointing this out. We agree with this comment. Therefore, we have expanded on section 3.2.1 accordingly to detail that larger scale clinical trials would be necessary to determine standardised correlates of protection. The revised material can be found on page 10, paragraph 5, line 40-48.
“Rather than relying on a single immune correlate similar to the HAI titre, future evaluation of UIVs will likely require a standardised panel of immune endpoints that integrate multiple complementary measures of protection. Depending on the vaccine platform, these may include stalk-directed neutralising antibodies, neuraminidase inhibition titres, Fc-mediated effector functions such as ADCC, mucosal secretory IgA responses and antigen-specific CD4+ and CD8+ T-cell immunity [31,39,167,168]. Prospective clinical studies correlating these immune responses with sufficient protection against laboratory-confirmed influenza infection will be essential to determine and predict vaccine efficacy [167,168].”
Comment 5: The authors should discuss how well-received they think these infection-permissive vaccines will be by vaccine recipients.
Response 5: We thank the reviewer for their comment and pointing this out. We agree with this comment. Therefore, we have expanded the Discussion to consider factors that may influenza vaccine acceptance. As there is no existing evidence which can be used to substantiate claims with certainty, we have given a nuanced estimation. The revised material can be found on page 12, paragraph4, line 23-31.
“Successful implementation of a UIV will also greatly depend on public acceptance [46,50]. The prospect of broader protection may improve vaccine acceptance by potentially reducing the need for repeated vaccination [50,53. However, as many UIV candidates are designed to elicit broad cross-protective immunity by attenuating disease severity rather than providing sterilising immunity, their infection-permissive mechanism may present challenges for public acceptance if vaccine efficacy is perceived solely as the ability to prevent infection [52,53]. Consequently, effective public health communication is essential to ensure the intended benefits of these vaccines are clearly understood by recipients [46,50].”
Comment 6: It seems that the immunological imprinting aspect could be overcome with a proper balance of seasonal vaccine and different universal vaccines. However, this would need to be tightly coordinated to enhance immunity appropriately in individual patients. This may be a theoretical possibility that may not be achievable in a real-world setting.
Response 6: We thank the reviewer for their comment and pointing this out. We agree with this comment. Therefore, we have expanded section 3.6 to consider the possibility of modifying immune responses while also acknowledging the challenges associated with their implementation and the need for further clinical studies to establish feasibility. The revised material can be found on page 14, paragraph 5, lines 29-36.
“Although immune imprinting is often regarded as a barrier to achieving broad immunity, accumulating evidence suggests that it may not be entirely fixed and could potentially be modified through sequential antigenic exposure [31,39]. Consequently, an important area of future research will be determining whether UIVs can potentially redirect immune responses towards conserved viral epitopes despite pre-existing immune biases. However, the extent to which established imprinting can be reshaped remains uncertain and is likely to vary according to host-related factors such as age, exposure history and immune status [31,39].”